Citadel Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-28,290
| Closed | -$515K | – | 15698 |
|
|
2024
Q2 | $515K | Buy |
28,290
+12,114
| +75% | +$222K | ﹤0.01% | 7979 |
|
|
2024
Q1 | $298K | Sell |
16,176
-219
| -1% | -$4.07K | ﹤0.01% | 9464 |
|
|
2023
Q4 | $321K | Sell |
16,395
-2,026
| -11% | -$35.3K | ﹤0.01% | 9030 |
|
|
2023
Q3 | $330K | Sell |
18,421
-9,676
| -34% | -$189K | ﹤0.01% | 8981 |
|
|
2023
Q2 | $579K | Buy |
+28,097
| New | +$588K | ﹤0.01% | 7621 |
|
|
2023
Q1 | – | Sell |
-38,659
| Closed | -$865K | – | 15820 |
|
|
2022
Q4 | $865K | Buy |
38,659
+8,803
| +29% | +$198K | ﹤0.01% | 7082 |
|
|
2022
Q3 | $619K | Buy |
29,856
+2,671
| +10% | +$65K | ﹤0.01% | 7997 |
|
|
2022
Q2 | $632K | Buy |
27,185
+2,771
| +11% | +$66K | ﹤0.01% | 8122 |
|
|
2022
Q1 | $668K | Buy |
+24,414
| New | +$688K | ﹤0.01% | 8683 |
|
|
2021
Q4 | – | Sell |
-8,465
| Closed | -$347K | – | 15067 |
|
|
2021
Q3 | $347K | Sell |
8,465
-3,196
| -27% | -$135K | ﹤0.01% | 10740 |
|
|
2021
Q2 | $467K | Sell |
11,661
-19,083
| -62% | -$712K | ﹤0.01% | 10199 |
|
|
2021
Q1 | $1.09M | Buy |
30,744
+13,746
| +81% | +$515K | ﹤0.01% | 7903 |
|
|
2020
Q4 | $529K | Buy |
16,998
+9,287
| +120% | +$283K | ﹤0.01% | 8048 |
|
|
2020
Q3 | $213K | Buy |
+7,711
| New | +$227K | ﹤0.01% | 8709 |
|
Other funds holding GERM
Citadel Advisors's GERM Position: Q3 2024 in Review
Citadel Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 28,290 shares — an estimated $515K sold.
Citadel Advisors first reported a position in GERM in Q3 2020 and held it in 14 quarters. The position peaked at $1.09M in Q1 2021. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.
- Citadel Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 28,290 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $515K.
- Citadel Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 14 quarters.
- Citadel Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $1.09M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.